Skip to main content
. 2012 Aug 1;287(39):32913–32921. doi: 10.1074/jbc.M112.386680

FIGURE 6.

FIGURE 6.

Complement inhibition of MAP-1. A, shown is dose-dependent deposition of C3 (left) and C9 (right) on solid phase mannan. Serum from a homozygous D/D MBL defect serum ± reconstitution with 0.4 μg/ml recombinant MBL preincubated on the mannan-coated wells is shown. B and C, dose-dependent MAP-1 inhibition of the MBL-dependent activation and deposition of C3 (B) and C9/terminal complement complex (C) is shown. rMBL at a concentration of 400 ng/ml was applied to mannan-coated microtiter plates followed by incubation with serial dilutions of rMAP-1. MBL defect serum of the D/D genotype (serum concentrations are shown in the x axis) was subsequently incubated with the MBL/MAP-1 complexes, and the activation and deposition of endogenous C3 or C9 were measured with specific monoclonal antibodies. The different curves illustrate the dose-dependent MAP-1 inhibition of the MBL-dependent activation and deposition of C3. Error bars indicate two times the S.D. of double determinations.